Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: perspectives from the United States and China

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: perspectives from the United States and China

PurposeThe efficacy of tislelizumab plus chemotherapy in improving progression-free survival (PFS) and overall survival (OS) in unresectable gastric or gastroesophageal junction cancer (GC/GEJC) has recently been emphasized. This study compared the cost-effectiveness of tislelizumab plus chemotherap...

Full description

Saved in:
Bibliographic Details
Main Authors: Wenwang Lang, Qi Ai, Wenwen Zhang, Qinling Jiang, Yulong He, Ming Ouyang
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Pharmacology
Subjects:
cost-effectiveness
unresectable gastric cancer
unresectable gastroesophageal junction cancer
tislelizumab
Markov model
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1461571/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1461571/full

Similar Items